Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers, particularly through its product, bexmarilimab, targeting the Clever-1 receptor.

Faron Pharmaceuticals Ltd.

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 6:39 PM	432712d4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 6:39 PM	97a000e9
crunchbase trigger	general	Nov 27, 2024 12:50 PM	01d97d38
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 27, 2024 6:39 PM	8e1c4606
news basic	general	Sep 27, 2024 6:39 PM	654fc1e3
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FARON

Faron Pharmaceuticals Ltd.

Last Close

142.50

22/11 14:00

Market Cap

1.36M

Beta: -

Volume Today

20.05K

Avg: -